PROKIDNEY CORP.

Listed Company

PROKCIK 0001850270NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)E9FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-68.99M

Total Assets

$335.57M

Equity

$-1.01B

Shares Out

—

Op. Cash Flow

$-120.12M

PROK$1.63−53.95% · past yearDBEQ Basic

Daily closing prices

Business

ProKidney Corp. is a late-clinical-stage biopharmaceutical company developing rilparencel, a first-in-class autologous cell therapy for advanced chronic kidney disease and type 2 diabetes. Rilparencel comprises selected renal cells derived from a patient's own kidney tissue, expanded and reinjected via minimally invasive outpatient procedure. The company operates a single development program focused on Phase 3 clinical trials (PROACT 1/REGEN-006) in the United States, Mexico, and Taiwan, with manufacturing conducted at its Winston-Salem, North Carolina facility. ProKidney pursues regulatory approval through the FDA's accelerated approval and RMAT designation pathways.

Summary from 10-K filed 2026-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	893,000	76,000	0	0	—
Research and development	114	128	107	82	46
General and administrative	52	56	45	71	9
Total operating expenses	166	184	152	153	55
Operating loss	−165	−184	−152	−153	−55
Interest income	14	20	22	6	2,000
Interest expense	−4,000	−9,000	−12,000	−215,000	0
Net loss before income taxes	−151	−164	−129	−147	−55
Income tax (benefit) expense	414,000	−598,000	6	896,000	38,000
Net loss before noncontrolling interest	−152	−163	−135	−148	−55
Net loss attributable to noncontrolling interest	−83	−102	−100	−40	0
Net loss available to Class A ordinary shareholders	−69	−61	−35	—	−55

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	109	99	61	490	21
Marketable securities	161	259	302	0	—
Interest receivable	1	2	1	0	—
Prepaid assets	3	4	3	3	588,000
Prepaid clinical	4	12	6	10	6
Assets held for sale	0	19	0	—	—
Other current assets	3	80,000	9,000	1	25,000
Total Current Assets	281	396	374	505	27
Fixed assets, net	51	42	42	11	11
Right of use assets, net	4	3	4	2	1
Total assets	336	441	421	518	40
Accounts payable	940,000	4	5	3	3
Lease liabilities	1	765,000	803,000	493,000	267,000
Accrued expenses and other	29	31	18	7	9
Income taxes payable	0	682,000	1	0	—
Total current liabilities	31	36	25	11	12
Income tax payable, net of current portion	1	748,000	568,000	278,000	0
Lease liabilities, net of current portion	3	2	4	2	1
Total liabilities	35	39	29	13	13
Commitments and Contingencies	—	—	—	—	—
Redeemable noncontrolling interest	1,312	1,397	1,495	1,602	0
Additional paid-in capital	259	206	36	7	0
Accumulated other comprehensive gain	56,000	130,000	130,000	0	—
Accumulated deficit	−1,270	−1,201	−1,140	−1,104	−162
Total shareholders' deficit	−1,011	−995	−1,103	−1,097	27
Total liabilities and shareholders' deficit	336	441	421	518	40

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	7	5	4	3	2
Equity-based compensation	25	29	31	74	699,000
Gain on marketable securities, net	−3	−7	−6	0	—
Gain on lease disposition	−29,000	−161,000	0	0	—
Impairment charges	318,000	5	0	0	—
Loss on disposal of equipment	1	56,000	23,000	0	0
Interest receivable	1	−1	−1	0	—
Prepaid and other assets	6	−6	5	−7	−6
Accounts payable and accrued expenses	−6	12	12	494,000	8
Income taxes payable	−356,000	−609,000	2	278,000	0
Net cash flows used in operating activities	−120	−126	−90	−77	−50
Proceeds from sale of facility	18	0	0	—	—
Purchases of marketable securities	−217	−324	−472	0	0
Sales and maturities of marketable securities	318	374	176	0	0
Purchase of equipment and facility expansion	−15	−30	−34	−2	−5
Net cash flows provided by (used in) investing activities	104	20	−330	−2	−5
Proceeds from sales of Class A ordinary shares, net of offering costs	24	144	0	0	0
Payments on finance leases	−26,000	−54,000	−52,000	−32,000	−30,000
Exercise of stock options	1	140,000	0	0	—
Net cash flows provided by (used in) financing activities	26	144	−10	549	71
Net change in cash and cash equivalents	9	38	−430	470	16
Right of use assets obtained in exchange for lease obligations	2	3	3	1	0
Exchange of Class B ordinary shares	5	15	10	—	—
Impact of equity transactions and compensation on redeemable noncontrolling interest	3	19	3	6	0
Equipment and facility expansion included in accounts payable and accrued expenses	131,000	347,000	218,000	51,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is PROKIDNEY CORP.'s CIK number?

PROKIDNEY CORP.'s SEC CIK number is 0001850270 (1850270). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find PROKIDNEY CORP.'s SEC filings?

All of PROKIDNEY CORP.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did PROKIDNEY CORP. last report earnings?

PROKIDNEY CORP. (PROK) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-225848). This is PROKIDNEY CORP.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is PROKIDNEY CORP.'s most recent earnings 8-K?

PROKIDNEY CORP.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001193125-26-225848. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View PROKIDNEY CORP.'s latest earnings 8-K →
Look up any company's CIK number →